Amedisys, a home health and hospice care company, said in a securities filing that Jeffrey Jeter, the company’s chief compliance officer, will take one year of paid leave under a new employment agreement between the company and Jeter. Under terms of the new agreement, Jeter will initially continue to be employed as chief compliance officer, the company stated.

Amedisys said the term of Jeter’s employment will continue through Aug. 1, 2017, unless his employment is terminated by either party in accordance with the agreement or the parties enter into a subsequent agreement extending or shortening his term of employment. “The agreement will be terminated upon Jeter’s death or disability and may be terminated by Jeter upon 30 days’ notice or by the company for ‘cause’ (as defined in the agreement),” the company stated in a Form 8-K, issued May 2.

Jeter will work full time for the company through July 31, 2016. Beginning on Aug. 1, 2016 and through the termination date, Jeter will be on an authorized paid leave of absence. Jeter agreed not to perform paid services, either as an owner, director, shareholder, employee or otherwise, for any other entity without the express written consent of the company’s chief HR officer.

In May 2015, Amedisys first announced in a securities filing that it was under investigation by the U.S. Department of Justice. In that filing, it disclosed that it had received a subpoena requesting the delivery of information regarding 53 identified hospice patients to the U.S. Attorney’s Office for the District of Massachusetts.

It also requested the delivery of documents relating to the company’s hospice clinical and business operations and related compliance activities, the filing stated. The subpoena generally covers the period from January 2011 through the present.

“The company is fully cooperating with the U.S. Department of Justice with respect to this investigation. No assurance can be given as to the timing or outcome of this investigation.”